

**WHAT IS CLAIMED IS:**

1. A pharmaceutical composition comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in a ratio by weight of 1:500 to 500:1.
2. The pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 1 wherein the 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine is in the form of a pharmaceutically acceptable salt.
4. The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable salt is the hydrochloride.
5. The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable salt is the maleate.
6. A method for the prevention of diseases caused by thrombus or embolus, comprising administering a pharmaceutical composition comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.
7. A method according to claim 6, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.
8. A method according to claim 6 or claim 7, in which the warm-blooded animal is a human.

9. A method for the treatment of diseases caused by thrombus or embolus, comprising administering a pharmaceutical composition comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.
10. A method according to claim 9, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.
11. A method according to claim 9 or claim 10, in which the warm-blooded animal is a human.
12. A method for the treatment of a patient undergoing stenting, angioplasty, and/or to prevent restenosis comprising administering a pharmaceutical composition comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.
13. A method according to claim 12, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.
14. A method according to claim 12 or claim 13, in which the warm-blooded animal is a human.